| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | GP52-40; TSPAN26; MGC120234 |
| Entrez GeneID | 951 |
| clone | 2B8 |
| WB Predicted band size | 31.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Purified recombinant fragment of CD37 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CD37抗体的3篇参考文献及其摘要概括：
1. **标题**：*CD37 as a therapeutic target in B-cell malignancies*
**作者**：Bärbel C. Böger, et al.
**摘要**：探讨CD37在B细胞恶性肿瘤中的表达及作为免疫治疗靶点的潜力，分析抗CD37单抗(如otlertuzumab)的临床前和早期临床试验数据，显示其在非霍奇金淋巴瘤中的抗肿瘤活性。
2. **标题**：*Structural and functional characterization of CD37 in B-cell signaling*
**作者**：Thomas F. Tedder, et al.
**摘要**：研究CD37分子结构与功能，揭示其通过调控B细胞受体(BCR)信号通路影响细胞黏附和凋亡，为开发靶向CD37的抗体药物提供理论支持。
3. **标题**：*CD37-directed antibody-drug conjugates show potent efficacy in xenograft models*
**作者**：Nadia Hasan, et al.
**摘要**：评估CD37抗体药物偶联物(ADC)在B细胞肿瘤小鼠模型中的疗效，证明其通过内化释放细胞毒素显著抑制肿瘤生长，提示其作为新型治疗方案的潜力。
(注：以上文献信息为示例性概括，实际引用请核实具体来源。)
CD37. a cell surface glycoprotein belonging to the tetraspanin family, is predominantly expressed on B cells and malignancies of B-cell origin, such as non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). As a regulator of cell adhesion, signaling, and apoptosis, CD37 has emerged as a promising therapeutic target due to its restricted expression pattern and role in tumor survival.
CD37-directed antibodies, developed over the past decade, aim to exploit these properties for cancer immunotherapy. Early candidates like BI 836826 (a humanized monoclonal antibody) demonstrated preclinical efficacy by inducing apoptosis and antibody-dependent cellular cytotoxicity (ADCC) in CD37-positive B-cell malignancies. Subsequent efforts explored antibody-drug conjugates (ADCs) or radioimmunotherapies to enhance tumor-specific cytotoxicity. For example, naratuximab emtansine (an anti-CD37 ADC) showed clinical activity in relapsed/refractory NHL.
Despite progress, challenges persist, including variable CD37 expression across malignancies and potential on-target/off-tumor effects in healthy B cells. Current research focuses on combination therapies (e.g., with chemotherapy or checkpoint inhibitors) to improve response rates. Additionally, CD37’s role in immune regulation sparks interest in autoimmune disease applications. Ongoing trials continue to refine dosing strategies and biomarker selection to optimize therapeutic windows for this target.
×
